Log in

Relevant bibliographies by topics / An agonist of beta-blockers

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'An agonist of beta-blockers'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'An agonist of beta-blockers.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "An agonist of beta-blockers"

1

Fitzgerald, J. D. "Do partial agonist beta-blockers have improved clinical utility?" Cardiovascular Drugs and Therapy 7, no. 3 (1993): 303–10. http://dx.doi.org/10.1007/bf00880153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Yoshikawa, Tsutomu. "Inverse Agonism of Beta-Blockers." Journal of Cardiac Failure 11, no. 9 (2005): S244. http://dx.doi.org/10.1016/j.cardfail.2005.08.045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Van, An Thi Minh, and Nawaid Ahmad. "Selective Beta-Blockers on Chronic Obstructive Pulmonary Disease: A Literature Review." Respiratory Science 4, no. 3 (2024): 180–96. http://dx.doi.org/10.36497/respirsci.v4i3.131.

Full text

Abstract:

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are usually coexisting. While beta-blockers are the indispensable management of an array of cardiovascular diseases, inhaled beta-receptor agonists are the central treatment for COPD patients. This review aims to assess the effect of beta-blockers on exacerbation rate, mortality, and quality of life among the COPD population. After the search on Cochrane Library, Pubmed, and Scopus, 15 relevant full-text articles published between 2012 and 2022 were included. We compared selective beta-blockers versus either non-user

APA, Harvard, Vancouver, ISO, and other styles

4

London, Martin J. "Beta blockers and alpha2 agonists for cardioprotection." Best Practice & Research Clinical Anaesthesiology 22, no. 1 (2008): 95–110. http://dx.doi.org/10.1016/j.bpa.2007.09.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

TURABI, AFTAB, Naseer Baluch, S. SAUD HASAN, Mehar Ali, and AHMED DANYAL. "ADRENALINE & ITS ANTAGONIST." Professional Medical Journal 12, no. 04 (2005): 420–25. http://dx.doi.org/10.29309/tpmj/2005.12.04.5093.

Full text

Abstract:

Objective: This research work deals with the mechanism involved in determining the therapeuticpotential of adrenaline and its blockers in gastrointestinal motility. Method: The classical method of Craig & Clark wasused for obtaining the longitudinal and circular muscles strip of rabbit intestine for in-vitro studies. Each muscle stripseparately was subjected to the effect of adrenaline and its blockers. The results were recorded on polygraphapparatus. Results: The effects were recorded in vice versa fashion i.e. agonist v/s antagonist and antagonist v/sagonist on each muscle strip separate

APA, Harvard, Vancouver, ISO, and other styles

6

Gough, N. R. "-Blockers: Both Antagonist and Agonist." Science Signaling 1, no. 39 (2008): ec336-ec336. http://dx.doi.org/10.1126/scisignal.139ec336.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Thor, Doreen, Angela Schulz, Thomas Hermsdorf, and Torsten Schöneberg. "Generation of an agonistic binding site for blockers of the M3 muscarinic acetylcholine receptor." Biochemical Journal 412, no. 1 (2008): 103–12. http://dx.doi.org/10.1042/bj20071366.

Full text

Abstract:

GPCRs (G-protein-coupled receptors) exist in a spontaneous equilibrium between active and inactive conformations that are stabilized by agonists and inverse agonists respectively. Because ligand binding of agonists and inverse agonists often occurs in a competitive manner, one can assume an overlap between both binding sites. Only a few studies report mutations in GPCRs that convert receptor blockers into agonists by unknown mechanisms. Taking advantage of a genetically modified yeast strain, we screened libraries of mutant M3Rs {M3 mAChRs [muscarinic ACh (acetylcholine) receptors)]} and ident

APA, Harvard, Vancouver, ISO, and other styles

8

Channer, KS, MA James, T. MacConnell, and JR Rees. "Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity [see comments]." British Journal of Clinical Pharmacology 37, no. 1 (1994): 53–57. http://dx.doi.org/10.1111/j.1365-2125.1994.tb04238.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Herxheimer, A. "Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity [letter; comment]." British Journal of Clinical Pharmacology 37, no. 6 (1994): 613–76. http://dx.doi.org/10.1111/j.1365-2125.1994.tb04313.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Wang, H. Y., M. Berrios та C. C. Malbon. "Localization of β-adrenergic receptors in A431 cells in situ. Effect of chronic exposure to agonist". Biochemical Journal 263, № 2 (1989): 533–38. http://dx.doi.org/10.1042/bj2630533.

Full text

Abstract:

The status of beta-adrenergic receptors was investigated in A431 cells exposed to chronic stimulation by the beta-adrenergic agonist, (-)-isoproterenol. Specific binding of beta-adrenergic antagonist (-)-[125I]iodocyanopindolol declined to 60-80% below control values within 12 h of agonist treatment. This decline in ligand binding was also observed in high-speed membrane fractions prepared from agonist-treated cells. Immunoblots probed with anti-receptor antibodies revealed both that beta-adrenergic receptors from untreated and treated cells migrated as 65,000-Mr peptides and that the cellular

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "An agonist of beta-blockers"

1

Herepath, Michael Leonard. "Agonist-induced sensitivity changes at #beta#-adrenoceptors." Thesis, Cardiff University, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.328051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

McCaffrey, Patricia Marion. "Studies of agonist and partial agonist activity at the beta-adrenoceptor in man." Thesis, Queen's University Belfast, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.317034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Manio, Michael Magtoto. "In vivo exposure to lipopolysaccharide unmasks contractions to the alpha2-adrenergic agonist dexmedetomidine in the rat aorta." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/208015.

Full text

Abstract:

Dexmedetomidine is α2-adrenergic agent and commonly used in the intensive care setting. It is used primarily to sedate critically ill patients in various surgical, endoscopic and radiologic procedures. This medication gained superiority with other sedatives with a distinct advantage of less depression of the respiratory system. Although dexmedetomidine is often administered to septic patients, the vascular effect has not been fully studied in this clinical setting. In this thesis, rats were administered saline or bacterial lipopolysaccharide (LPS) 1, 10 and 20 mg/kg. Aortic rings were obtai

APA, Harvard, Vancouver, ISO, and other styles

4

Tran, Tung Vu. "Ocular Hypotensive Effect of the α2-Adrenergic Agonist, Lofexidine". Thesis, University of North Texas, 1989. https://digital.library.unt.edu/ark:/67531/metadc501156/.

Full text

Abstract:

A selective a2-adrenergic agonist, lofexidine, significantly reduced intraocular pressure (lOP) in intact ocular normotensive NZW rabbits, producing a differential dose-dependent decrease in IOP in'the ipsilateral and contralateral eye. Contralateral IOP reduction was most observable at low doses. Unilateral superior cervical ganglionectomy and extraocular muscle excision studies were undertaken to elucidate the factors influencing differential IOP reduction by lofexidine. Similar significant contralateral decreases in IOP were noted when the agent was applied to either the intact or operated

APA, Harvard, Vancouver, ISO, and other styles

5

Santos, Antonio Carlos Ramos dos. "Efeitos do período de administração de cloridrato de zilpaterol e do tempo de confinamento no desempenho, características de carcaça e qualidade de carne de bovinos Nelore." Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/11/11139/tde-16042015-110758/.

Full text

Abstract:

O objetivo desta pesquisa foi avaliar os efeitos do período de administração de cloridrato de zilpaterol (CZ) e do tempo de confinamento no desempenho, características de carcaça, rendimento de cortes cárneos comerciais e na qualidade de carne de bovinos Nelore. Foram utilizados 96 bovinos machos não castrados da raça Nelore, com peso vivo inicial de 377 ± 25,1 kg. O delineamento utilizado foi o de blocos completos casualizados em esquema fatorial 4 × 2, sendo quatro períodos de administração com CZ (0, 20, 30 ou 40 dias) e dois tempos de confinamento (90 ou 117 dias). O período de suplementaç

APA, Harvard, Vancouver, ISO, and other styles

6

Parr, Timothy. "Calpain proteinase mRNA and beta-agonist induced muscle growth." Thesis, University of Nottingham, 1991. http://eprints.nottingham.ac.uk/11445/.

Full text

Abstract:

The mechanism by which β-agonists induce skeletal muscle hypertrophy is believed largely to be through a reduction in protein degradation. These growth promoters are also known to effect the activity of the calcium dependent proteinases (calpains) and their specific endogenous inhibitor calpastatin. The changes in activity appear to be toward a decrease in the calpain system's proteolytic potential. In this study attempts were made to determine whether the altered activity of the enzymes and inhibitor were brought about by induced changes in gene expression as reflected by altered levels of sp

APA, Harvard, Vancouver, ISO, and other styles

7

Lortie, Michel B. "The rainbow trout muscle beta(2)-adrenoceptor system: Impact of beta(2)-agonist feeding." Thesis, University of Ottawa (Canada), 2002. http://hdl.handle.net/10393/6268.

Full text

Abstract:

Previous studies showed that beta2-adrenergic agonists (beta 2-AAs) enhanced muscle growth and reduced lipid deposition in animals of agricultural and economical importance, including teleost fish. The goal of the present study was to provide a mechanistic explanation underlying the reported beta2-AA-induced muscle growth in the rainbow trout (Oncorhynchus mykiss). Using radioligand binding assays and adenylyl cyclase/cAMP assays, this study characterized and demonstrated the presence of functional beta2-adrenoceptors (beta2-ARs) on red and white muscle membranes. Trout fed 40 ppm of two beta2

APA, Harvard, Vancouver, ISO, and other styles

8

Nieland, Nick. "Investigations of derivatives of 14#beta#-amino-7,8-dihydromorphinone." Thesis, University of Bristol, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.265328.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Arnold, Ian Robert. "In vivo regulation of cardiac beta-adrenoceptors by a partial agonist." Thesis, University of Leicester, 1993. http://hdl.handle.net/2381/35645.

Full text

Abstract:

Chronic therapy with the beta1 selective partial agonist xamoterol is not associated with the tolerance seen with agonists of greater intrinsic activity. In order to investigate whether this could be explained by the effect of xamoterol on the in vivo regulation of cardiac beta-adrenoceptors, 2 studies have been performed. 40 right atrial biopsies were obtained from 55 patients prospectively randomised in a double blind fashion to receive either xamoterol or the beta1 selective antagonist atenolol (previously shown to upregulate beta1-adrenoceptors and enhance beta2 mediated responses) for at

APA, Harvard, Vancouver, ISO, and other styles

10

Gangadharan, Denise Michelle. "Thymic development of CS8[alpha][alpha]⁺ TCR[alpha][beta]⁺ agonist selected IEL." Diss., Connected to a 24 p. preview or request complete full text in PDF format. Access restricted to UC campuses, 2005. http://wwwlib.umi.com/cr/ucsd/fullcit?p3189998.

Full text

Abstract:

Thesis (Ph. D.)--University of California, San Diego, 2005.<br>Title from first page of PDF file (viewed Marc 6, 2006). Available via ProQuest Digital Dissertations. Vita. Includes bibliographical references (p. 100-116).

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "An agonist of beta-blockers"

1

Cleophas, Ton J. M. Beta-blockers in hypertension and angina pectoris: Different compounds, differenct strategies. Kluwer Academic Publishers, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Richard, Beasley, and Pearce Neil, eds. The Role of beta receptor agonist therapy in asthma mortality. CRC Press, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Elliott, Christopher Trevor. Detection of residues of the beta-agonist clenbuterol in medicated farm animals. The Author], 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Zug, Naser Abd-Asalam. Studies of the bronchodilator action of the long acting [beta]2-agonist (salmeterol) in normal human subjects. University of Manchester, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Momoka, Endo, and Matsumoto Nanami, eds. Beta blockers: New research. Nova Science Publishers, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Prichard, Brian N. C. 1932-, ed. Beta-blockers in clinical practice. Churchill Livingstone, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cruickshank, J. M. Beta-blockers in clinical practice. Churchill Livingstone, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

1948-, Deedwania Prakash C., ed. Beta-blockers and cardiac arrhythmias. M. Dekker, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

1936-, Saunders Kenneth B., European Society for Clinical Respiratory Physiology., and European Society of Pneumology, eds. Formoterol: A long-acting B2-agonist for the management of asthma : an international symposium held during the joint meeting of SEP and SEPCR, London, 1990. Hogrefe & Huber, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Fritz, Bärbel. Zur Wirkung des [beta]2-Sympathomimetikums [Beta-Sympathomimetikums] Clenbuterol und des [beta]-Blockers [Beta-Blockers] Carazolol auf das Myometrium der Ratte unter Östrogeneinfluss. [s.n.], 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "An agonist of beta-blockers"

1

Centner, Terence J. "Health concerns with beta agonist feed additives." In Consumers, Meat and Animal Products. Routledge, 2019. http://dx.doi.org/10.4324/9780429430572-11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Anderson, Gary. "Formoterol, a new long-acting β2-agonist." In Treatment of Asthma: The long-acting beta-2-agonists. Springer Vienna, 1998. http://dx.doi.org/10.1007/978-3-7091-7513-2_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Shrivastava, Deepak. "Deprescribing Long-Acting Beta Agonist and Other Inhalers." In Talking Points on Deprescribing in Hospice Care. CRC Press, 2024. http://dx.doi.org/10.1201/9781003392149-24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Johnson, Malcolm. "Development of the long-acting β2-agonist, salmeterol." In Treatment of Asthma: The long-acting beta-2-agonists. Springer Vienna, 1998. http://dx.doi.org/10.1007/978-3-7091-7513-2_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Svensson, Leif-Ake. "Development of bambuterol; a long acting, orally active beta-agonist prodrug." In Treatment of Asthma: The long-acting beta-2-agonists. Springer Vienna, 1998. http://dx.doi.org/10.1007/978-3-7091-7513-2_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Matthews, Jeffrey. "Long-acting Beta-agonist Plus Inhaled Corticosteroid in COPD (TORCH)-2007." In Top Articles in Primary Care. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-25620-2_66.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tyrer, Peter J., Mark Slifstein, Joris C. Verster, et al. "Beta-Blockers." In Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_3106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

López-de-Sá, Esteban, and José López-Sendón. "Beta-Blockers." In Pharmacological Treatment of Chronic Stable Angina Pectoris. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-17332-0_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Chaubey, Vikas P., Kevin B. Laupland, Christopher B. Colwell, et al. "Beta-Blockers." In Encyclopedia of Intensive Care Medicine. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_186.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hill, Keith, Tom Baranowski, Walter Schmidt, et al. "Beta-Blockers." In Encyclopedia of Exercise Medicine in Health and Disease. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-540-29807-6_2143.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "An agonist of beta-blockers"

1

Ganta, Ashwin, Ratna Priya Gangi, Wilson Gonsalves, Sonica Saini, and Tammy Wichman. "Inhalational Beta Agonist Induced Lactic Acidosis." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1343.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Thorsen, Terje, and Holm Holmsen. "PLATELET ACTIVATION AND AGGREGATION BY GAS BOBBLES IN VITRO." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643759.

Full text

Abstract:

After diving, in decompression sickness and after extra-corporeal circulation in membrane oxygenators, there is often a reductionin the number of circulating platelets. Gas bubbles seem to be the common denominator for these quite different conditions, and it is assumed that gas bubbles activate the platelets although by unknown mechanisms. We have used gas bubbles as a platelet agonist in an aggregometer-like apparatus. The bubbles produced platelet aggregation similar to that caused by "classical" agonists,e.g.,ADP, epinephrine etc. The gas-liquidinterface was essential for this aggregation,

APA, Harvard, Vancouver, ISO, and other styles

3

Bajwa, G., D. Guadarrama, and R. El-Bizri. "Heartbreaking Consequences of Beta-Agonist Therapy in Asthma." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a3497.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Robinson, D., A. A. Liou, J. Besas, et al. "Association of Takotsubo Cardiomyopathy and Beta-Agonist Use in Asthmatics." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a5638.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Anderson, William, Rahul Gondalia, Heather Hoch, et al. "Nighttime short-acting beta-agonist (SABA) in asthma and COPD." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa859.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Weathington, N. M., H. Wong, K. Chen, et al. "Immunometabolism of Alveolar Macrophages Is Modulated by Beta Agonist Exposure." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2909.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wong, R., B. Desai, U. Srivastava, et al. "Micrornas and Short-Acting Beta-2 Agonist Usage in Asthma." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Baernthaler, T., S. Ding, M. Chioccioli, et al. "Antifibrotic Effects of Sobetirome, a Thyroid Hormone Receptor Beta Agonist." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3722.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Liggett, S. B., D. Kim, A. Tokmakova, M. Giulianotti, S. An, and W. Goddard. "Discovery and Characterization of the First Biased Beta-Agonist That Favors Gs-Coupling vs Beta-Arrestin Mediated Desensitization: A New Class of Structurally Distinct Beta-Agonists for Treating Obstructive Lung Diseases." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3249.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Sobradillo Ecenarro, Patricia, Nuria Marina, Silvia Pérez-Fernández, Eva Tabernero, Milagros Iriberri, and Bartolomé Celli. "Paradoxical bronchoconstriction after administration of beta-2 agonist bronchodilators in COPD patients." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa3437.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "An agonist of beta-blockers"

1

Rafaeli, Ada, and Russell Jurenka. Molecular Characterization of PBAN G-protein Coupled Receptors in Moth Pest Species: Design of Antagonists. United States Department of Agriculture, 2012. http://dx.doi.org/10.32747/2012.7593390.bard.

Full text

Abstract:

The proposed research was directed at determining the activation/binding domains and gene regulation of the PBAN-R’s thereby providing information for the design and screening of potential PBAN-R-blockers and to indicate possible ways of preventing the process from proceeding to its completion. Our specific aims included: (1) The identification of the PBAN-R binding domain by a combination of: (a) in silico modeling studies for identifying specific amino-acid side chains that are likely to be involved in binding PBAN with the receptor and; (b) bioassays to verify the modeling studies using mut

APA, Harvard, Vancouver, ISO, and other styles

2

Skinner, Jonathan, and Douglas Staiger. Technology Adoption From Hybrid Corn to Beta Blockers. National Bureau of Economic Research, 2005. http://dx.doi.org/10.3386/w11251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Wang, Junwei, and Xin Zhou. Beta-blockers in colorectal cancer: a systematic review andmeta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.3.0077.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Wu, Xiaoqi, Jisen Zhao, Maoxia Fan, and Dongo Guo. Quality of Evidence Supporting the Effects of Xinmailong injection in Heart Failure: An Overview of Systematic Reviews and Meta-Analyses. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.10.0023.

Full text

Abstract:

Review question / Objective: 2.1.1 type of research SRs/MAs of RCT (randomized controlled trial) of Xinmailong injection for the treatment of heart failure. 2.1.2 Subject investigated All included patients met internationally recognized diagnostic criteria for heart failure.There are no limitations on age, gender, ethnicity, time of onset, source of cases and language of publication. 2.1.3 Type of Intervention The control group was treated with conventional basic Western medicine recommended by the guidelines related to heart failure[1, 11], including antiplatelet drugs, anticoagulants, vasodi

APA, Harvard, Vancouver, ISO, and other styles

5

Sentcоv, Valentin, Andrei Reutov, and Vyacheslav Kuzmin. Electronic training manual "Acute drug poisoning". SIB-Expertise, 2024. http://dx.doi.org/10.12731/er0776.29012024.

Full text

Abstract:

The widespread use in modern medicine of hypnotics, sedatives, tricyclic antidepressants, antihypertensive drugs and antipyretics, even in therapeutic dosages, sometimes leads to adverse consequences for the patient. Accidental or intentional excess of therapeutic dosages leads to severe poisoning. This fact indicates the high relevance of doctors’ knowledge of any clinical specialty and the treatment of poisoning by these groups of drugs. This electronic educational resourse consists of six theoretical educational modules: poisoning with barbituric acid derivatives, acute poisoning with tricy

APA, Harvard, Vancouver, ISO, and other styles

6

Beta-3 agonists in the management of detrusor overactivity. BJUI Knowledge, 2017. http://dx.doi.org/10.18591/bjuik.0051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!